Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Assets Average (2016 - 2025)

Historic Assets Average for Zevra Therapeutics (ZVRA) over the last 10 years, with Q3 2025 value amounting to $263.2 million.

  • Zevra Therapeutics' Assets Average rose 5668.37% to $263.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $263.2 million, marking a year-over-year increase of 5668.37%. This contributed to the annual value of $175.2 million for FY2024, which is 2182.63% up from last year.
  • Zevra Therapeutics' Assets Average amounted to $263.2 million in Q3 2025, which was up 5668.37% from $214.5 million recorded in Q2 2025.
  • Zevra Therapeutics' 5-year Assets Average high stood at $263.2 million for Q3 2025, and its period low was $50.8 million during Q1 2021.
  • For the 5-year period, Zevra Therapeutics' Assets Average averaged around $144.4 million, with its median value being $135.1 million (2021).
  • Per our database at Business Quant, Zevra Therapeutics' Assets Average skyrocketed by 110522.46% in 2021 and then tumbled by 1514.26% in 2023.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Assets Average stood at $135.1 million in 2021, then decreased by 13.04% to $117.4 million in 2022, then soared by 32.53% to $155.7 million in 2023, then grew by 18.75% to $184.8 million in 2024, then skyrocketed by 42.39% to $263.2 million in 2025.
  • Its last three reported values are $263.2 million in Q3 2025, $214.5 million for Q2 2025, and $175.4 million during Q1 2025.